Picture of Neogenomics logo

NEO — Neogenomics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapFalling Star

Momentum

Relative Strength (%)
1m-33%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-50.48%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue$m231.81240.25276.74408.83444.45484.66562.0834.81%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/a+63.92-89.99n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Neogenomics EPS forecast chart

Profile Summary

NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
October 29th, 1998
Public Since
December 10th, 2012
No. of Shareholders
665
No. of Employees
1,700
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
123,122,449

NEO Share Price Performance

Similar to NEO

Picture of Akumin logo

Akumin

us flag iconNASDAQ Capital Market

Picture of Apollo Medical Holdings logo

Apollo Medical Holdings

us flag iconNASDAQ Capital Market

Assure Holdings

us flag iconNASDAQ Capital Market

Picture of Cryo-Cell International logo

Cryo-Cell International

us flag iconNASDAQ Capital Market

Picture of DLH Holdings logo

DLH Holdings

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email